Maxim Group analyst Jason McCarthy maintained a Buy rating on Vyome Holdings yesterday and set a price target of $15.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jason McCarthy has given his Buy rating due to a combination of factors influencing Vyome Holdings’ potential growth. The company’s key asset, VT1953, a topical gel for malignant fungating wounds, is expected to deliver top-line Phase 2 data by the end of 2025. If these results are positive, it could significantly boost the stock as the company plans to engage with the FDA for a potential pivotal trial.
Additionally, Vyome Holdings is advancing VT1908, an eye drop solution for anterior uveitis, which is set to enter clinical trials following an IND filing in the second half of 2026. This product leverages a 505(b)(2) pathway, potentially accelerating its development. McCarthy’s valuation incorporates these developments, applying risk adjustments and a discount rate to project a 12-month price target of $15, reflecting confidence in the company’s strategic direction and pipeline potential.